Journal Club 2024

journal club image

Want to be a Journal Club Presenter?

The next call for the January-June 2025 session speakers is now open.

Find out more and apply here!

Next HOPA Journal Club

Tuesday, November 19, 2024 at 2 p.m. Central Time

Listen to critical evaluations of hematology/oncology pharmacy publications resented by PGY2 Oncology Residents.

Reserve your spot for November's Journal Club!

Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma

Rachel Schneider, PharmD, PGY-2 Oncology Pharmacy Resident,

Froedtert & The Medical College of Wisconsin, Milwaukee, WI

Article: 

Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma

Efficacy and safety of lifileucel in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies

Anna Clare Eckrich, PharmD, PGY2 Oncology Pharmacy Resident,

Yale New Haven Health, New Haven, CT

Article:

Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144-01 study

Reserve your spot for November's Journal Club!

Featured Articles

Image of stem cell treatment

Tools and Resources

Pharmacist’s Application to Practice: Axatilimab-csfr

October 14, 2024

Sydney Hunt, PharmD, PGY-1 Pharmacist Resident, and Lindsay Orton, PharmD, BCOP, Stem Cell Transplant and Cellular Therapy Clinical Pharmacist, both from Vanderbilt University Medical Center, Nashville, TN, write about axatilimab-csfr (Niktimvo).

Tools and Resources

Pharmacist’s Application to Practice: Afamitresgene autoleucel

October 09, 2024

Emili Anderson, PharmD, PGY1 Acute Care Resident, and Roger Ngo, PharmD Candidate, both from UNC Medical Center, Chapel Hill, NC, write about afamitresgene autoleucel (afami-cel).

digital medical illustration of lung cancer in a person's chest

Tools and Resources

Pharmacist’s Application to Practice: Tarlatamab-dlle

September 26, 2024

SeongEun Emily Park, PharmD PGY2-Hematology/Oncology Pharmacy Resident Emory University Hospital Midtown/Winship Cancer Institute writes about tarlatamab-dlle.